The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Summa Health System
• Treatments: Bimatoprost; Latanoprost; Ophthalmic Solutions; Travoprost

Criteria

Inclusion Criteria:

• patients recently diagnosed with primary open angle glaucoma or ocular hypertension

• Caucasian and African American ethnicities

• Male and Female

• Age 30 and above

Exclusion Criteria:

• A history of ocular medication use within the last 12 months

• Inflammatory/ allergic skin diseases or dermatitis

• presence of periocular hyperpigmented skin lesions

• Systemic pigmentation disorders

• Use of systemic drugs that can affect skin pigmentation

• Visitation of tanning salons, or use of self tanning products

• Pregnancy or patients planning to become pregnant in the near future